Side-by-side · Research reference
5-Amino-1MQvsRetatrutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BPhase 2Reviewed10/41 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
01Mechanism of Action
Parameter
5-Amino-1MQ
Retatrutide
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Feedback intact?
—
—
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Retatrutide
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
12 mg / week (max efficacy)Jastreboff 2023
Phase 2 trial dose. Phase 3 dosing TBD.
Frequency
Once daily, fasted
Once weekly
Lower / starter dose
50 mg / day
—
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Phase 2 trial; Phase 3 ongoingJastreboff 2023
Duration
8–12 weeks per cycle
Indefinite for chronic indication (presumed)
Form
Oral capsule
—
Timing
Morning fasted preferred
Any time of day
Half-life
Hours (estimated; no human PK published)
~6 days (estimated from class)
Titration schedule
—
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
Reconstitution
—
Investigational; not commercially available
04Side Effects & Safety
Parameter
5-Amino-1MQ
Retatrutide
GI symptoms
Mild nausea (anecdotal)
Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Avoid (insufficient data)
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Glucose handling
—
Glycemic improvement; rare hyperglycemia from glucagon component
Pancreatitis risk
—
Class warning
Thyroid C-cell tumours
—
Class warning (presumed)
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
05Administration Protocol
Parameter
5-Amino-1MQ
Retatrutide
1. Form
Oral capsule. No injection.
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
2. Administration
Take with water, fasted preferred.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Morning fasted.
Once weekly, same day.
4. Storage
Room temp ≤25 °C, dry place.
Refrigerate 2–8 °C. Light-protected.
5. Caveat
Monitor B-vitamin status with chronic use.
27–31G, 4–8 mm insulin syringe.